A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque Psoriasis - PubMed
5 hours ago
- #Clinical trial
- #IL-23 inhibitor
- #Psoriasis treatment
- Picankibart, an IL-23p19 inhibitor, achieved significant skin clearance in Chinese patients with moderate-to-severe plaque psoriasis by Week 16.
- At Week 16, 80.3% of patients in the 200 mg picankibart group reached PASI 90, compared to 2.0% with placebo, and 93.5% achieved sPGA 0/1, versus 13.1% with placebo.
- All key secondary endpoints showed significant improvement with picankibart compared to placebo, with p-values less than 0.0001.
- Efficacy was maintained through Week 52 with dosing every 12 weeks using either 100 mg or 200 mg of picankibart, with no new safety concerns identified.
- The study was a Phase III trial conducted exclusively in Chinese patients and did not include an active comparator, which are noted as limitations.